A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.

Show simple item record

dc.contributor.author Rogers, Elaine en
dc.contributor.author MacLeod, Roderick en
dc.contributor.author Stewart, Joanna en
dc.contributor.author Bird, SP en
dc.contributor.author Keogh, JW en
dc.coverage.spatial England en
dc.date.accessioned 2012-04-02T01:30:46Z en
dc.date.issued 2011 en
dc.identifier.citation BMC Cancer 11:493 2011 en
dc.identifier.issn 1471-2407 en
dc.identifier.uri http://hdl.handle.net/2292/16335 en
dc.description.abstract Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progressed to the combination of agents.The combination of the anti-cachectic agent Eicosapentaenoic acid (EPA) and the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib has been tested in a small study with some benefit. The use of progressive resistance training (PRT) followed by the oral ingestion of essential amino acids (EAA), have shown to be anabolic on skeletal muscle and acceptable in older adults and other cancer groups.The aim of this feasibility study is to evaluate whether a multi-targeted approach encompassing a resistance training and nutritional supplementation element is acceptable for lung cancer patients experiencing cancer cachexia. en
dc.language eng en
dc.publisher BioMed Central en
dc.relation.ispartofseries BMC Cancer en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1471-2407/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Adult en
dc.subject Amino Acids, Essential en
dc.subject Cachexia en
dc.subject Carcinoma, Non-Small-Cell Lung en
dc.subject Combined Modality Therapy en
dc.subject Cyclooxygenase 2 Inhibitors en
dc.subject Dietary Supplements en
dc.subject Eicosapentaenoic Acid en
dc.subject Feasibility Studies en
dc.subject Female en
dc.subject Humans en
dc.subject Leucine en
dc.subject Lung Neoplasms en
dc.subject Male en
dc.subject Middle Aged en
dc.subject New Zealand en
dc.subject Patient Satisfaction en
dc.subject Prospective Studies en
dc.subject Pyrazoles en
dc.subject Resistance Training en
dc.subject Sulfonamides en
dc.title A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. en
dc.type Journal Article en
dc.identifier.doi 10.1186/1471-2407-11-493 en
pubs.begin-page 493 en
pubs.volume 11 en
dc.rights.holder Copyright: BioMed Central en
dc.identifier.pmid 22111896 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 277058 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Population Health en
pubs.org-id Gen.Practice& Primary Hlthcare en
dc.identifier.eissn 1471-2407 en
dc.identifier.pii 1471-2407-11-493 en
pubs.record-created-at-source-date 2012-04-02 en
pubs.dimensions-id 22111896 en


Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics